Renmin Hospital of Wuhan University

Running trials

• Not yet recruiting

  Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults

  NCT07835152· Phase 3· Brise Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

  NCT07792681· Phase 2/3· Brise Pharmaceuticals Co., Ltd.· Source

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· 4D Molecular Therapeutics· Source

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Antengene Biologics Limited· Source

• Recruiting

  Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC

  NCT07741448· Phase 2· Zhiquan Hu· Source

• Recruiting

  A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis

  NCT07692165· Phase 1/2· Innatus Therapeutics (Shanghai) Co., Ltd.· Source

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases

  NCT07595068· Renmin Hospital of Wuhan University· Source

• Recruiting

  Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension

  NCT07607275· Phase 4· Beijing Anzhen Hospital· Source

• Recruiting

  Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction

  NCT07587294· Renmin Hospital of Wuhan University· Source

• Recruiting

  Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

  NCT07632677· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• Recruiting

  A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

  NCT07450599· Phase 2· Bayer· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment

  NCT07896096· Phase 2· Renmin Hospital of Wuhan University· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women

  NCT07229976· Huazhong University of Science and Technology· Source

• Recruiting

  ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

  NCT06951646· Phase 2· Second Xiangya Hospital of Central South University· Source

• Not yet recruiting

  Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

  NCT07486479· Phase 3· The First Affiliated Hospital of Soochow University· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)

  NCT07401199· Qun Zhao· Source

• Recruiting

  Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial

  NCT07402525· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI-2 Trial

  NCT07361783· Chen Jing· Source

• Not yet recruiting

  A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

  NCT07365371· Phase 4· Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

  NCT07265570· Phase 2· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT06979336· Phase 2· Genentech, Inc.· Source

• Recruiting

  A Study of SKB518 in Patients With Lung Cancer

  NCT07019675· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

  NCT07038382· Phase 2· Shanghai Henlius Biotech· Source

• Recruiting

  The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis

  NCT07172035· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source

• Recruiting

  Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

  NCT07019012· Phase 4· Huazhong University of Science and Technology· Source

• Recruiting

  Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock

  NCT07085221· Renmin Hospital of Wuhan University· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Natural History Study of Inherited Retinal Diseases

  NCT07085533· Augelux Therapeutics· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Recruiting

  A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

  NCT06933472· Phase 3· Alebund Pharmaceuticals· Source

• Recruiting

  Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease

  NCT07267117· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Active, not recruiting

  Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

  NCT06806293· Phase 3· AbbVie· Source

• Recruiting

  Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

  NCT06754891· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Active, not recruiting

  Effect of CGM on Glucose Control in Non-insulin-treated Patients With Type 2 Diabetes Mellitus

  NCT06587438· Sinocare· Source

• Recruiting

  A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

  NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source

• Recruiting

  The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

  NCT06692972· China-Japan Friendship Hospital· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema

  NCT07515079· Phase 3· Bio-Thera Solutions· Source

Showing 50 of 103.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer9 recruiting
• Ulcerative colitis6 recruiting
• Colorectal cancer5 recruiting
• Crohn's disease5 recruiting
• Coronary artery disease4 recruiting
• Heart failure4 recruiting
• Chronic kidney disease3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Head and neck cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Migraine3 recruiting
• Type 2 diabetes3 recruiting
• Bladder cancer2 recruiting
• Diabetic eye disease2 recruiting
• High blood pressure2 recruiting
• Liver cirrhosis2 recruiting
• Macular degeneration2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Amyloidosis1 recruiting
• Aortic stenosis1 recruiting
• Atrial fibrillation1 recruiting
• Depression1 recruiting
• Hepatitis B1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Insomnia1 recruiting
• Lupus (SLE)1 recruiting
• Multiple myeloma1 recruiting
• Myasthenia gravis1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Pancreatic cancer1 recruiting
• Peripheral artery disease1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Terminated

  A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

  NCT07314060· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Brown Adipose Tissue Activity and NAFLD Progression

  NCT07825467· Renmin Hospital of Wuhan University· Source

• Completed

  Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

  NCT06717815· Phase 1/2· Nanjing Immunophage Biotech Co., Ltd· Source

• Completed

  Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

  NCT06631170· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06700499· Phase 2· Akeso· Source

• Completed

  A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

  NCT06422507· Phase 3· Bayer· Source

• Completed

  A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

  NCT06280716· Phase 3· Eli Lilly and Company· Source

• Completed

  Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06477237· Phase 3· Huabo Biopharm Co., Ltd.· Source

• Completed

  Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

  NCT06109818· Phase 2· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  Young-onset Colorectal Cancer Screening Based on Artificial Intelligence

  NCT06342622· Renmin Hospital of Wuhan University· Source

• Completed

  A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

  NCT05989048· Phase 3· Pfizer· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06092762· Phase 2· Akeso· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Completed

  Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis

  NCT06109805· Beijing Friendship Hospital· Source

• Completed

  YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

  NCT06048588· Phase 1/2· Beijing Inno Medicine Co., Ltd.· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study

  NCT06039748· Shenzhen Raysight Intelligent Medical Technology Co., Ltd.· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Clinical Management Strategies for Patients With Cirrhosis and Esophagogastric Varices Complicated by Early-stage Upper Gastrointestinal Cancer

  NCT07368309· Renmin Hospital of Wuhan University· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

  NCT05770609· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Alebund Pharmaceuticals· Source

• Completed

  A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

  NCT05919823· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

  NCT05810038· Phase 3· Pfizer· Source

• Completed

  A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

  NCT05265325· Phase 2· Kind Pharmaceuticals LLC· Source

• Completed

  Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

  NCT05949801· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

  NCT06066125· Phase 3· Akeso· Source

• Completed

  Study of Telitacicept in Generalized Myasthenia Gravis

  NCT05737160· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

  NCT05593575· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

  NCT05810948· Phase 2· argenx· Source

• Completed

  Evaluate Safety and Efficacy of Alveo HP Balloon Dilatation Catheter for Balloon Dilatation of Coronary Artery Stenosis

  NCT05998252· BrosMed Medical Co., Ltd· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source

• Completed

  Early Administration of Heparin At FMC for PPCI of STEMI Patients

  NCT05329155· Renmin Hospital of Wuhan University· Source

• Completed

  A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

  NCT05371652· Phase 3· Pfizer· Source

• Completed

  A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

  NCT05029921· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT05003245· Phase 3· Shanghai Henlius Biotech· Source

• Completed

  A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

  NCT05092841· Phase 3· Tasly GeneNet Pharmaceuticals Co., Ltd· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Bayer· Source

• Completed

  GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

  NCT05054751· Phase 3· Genor Biopharma Co., Ltd.· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

  NCT04888429· Phase 2· Qian Chu· Source

• Completed

  Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

  NCT04921384· Phase 3· H. Lundbeck A/S· Source

• Completed

  Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

  NCT04849351· Phase 2· Hutchison Medipharma Limited· Source

• Completed

  Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

  NCT04747496· Daiichi Sankyo· Source

• Completed

  Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

  NCT04643470· Phase 2· BeiGene· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

Showing 50 of 53.

Conditions

Diseases this institution publishes on or runs trials for.

• Gastric and oesophageal cancer37 works · 4 trials
• Ulcerative colitis25 works · 16 trials
• Depression24 works · 1 trial
• Polycystic ovary syndrome12 works · 0 trials